SCHEMBL7685541

SCHEMBL7685541

Cc1cccc([C@H]2c3[nH]c4ccccc4c3C[C@@H]3CN(C)CCN32)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
STAT3 P40763 1/20 0.49
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
HDAC3 O15379 1/20 0.45
PDE5A O76074 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7685549 1.00 MEN1 (0.51) MEN1KMT2ASTAT3LMNATP53
SCHEMBL7359519 0.82 PDE5A (0.60) PDE5A
SCHEMBL7360231 0.81 ABCG2 (0.51) HDAC3PDE5AHDAC4HDAC1HDAC7
SCHEMBL7419562 0.80 PDE5A (0.55) MEN1KMT2APDE5AMAPT
SCHEMBL7423296 0.76 PDE5A (0.58) HDAC3PDE5AHDAC4HDAC1HDAC7
SCHEMBL7423292 0.76 PDE5A (0.58) HDAC3PDE5AHDAC4HDAC1HDAC7
SCHEMBL7421542 0.76 PDE5A (0.58) HDAC3PDE5AHDAC4HDAC1HDAC7
SCHEMBL7423061 0.74 PDE5A (0.61) LMNAHDAC3PDE5AHDAC4HDAC1
SCHEMBL7423055 0.74 PDE5A (0.61) LMNAHDAC3PDE5AHDAC4HDAC1
SCHEMBL7366485 0.74 PDE5A (0.61) LMNAHDAC3PDE5AHDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035111-A1 Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives OSI PHARMACEUTICALS, INC. 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035111-A1 Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives MKI67, PNPO, CDK4 MEN1 756/4885KMT2A 1547/4885STAT3 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.